The novel somatostatin receptor 2/dopamine type 2 receptor chimeric compound BIM-23A758 decreases the viability of human GOT1 midgut carcinoid cells

Neuroendocrinology

Volumn 98, Issue 2, 2013, Pages 128-136

  Zitzmann, Kathrin ^a   Andersen, Sandra ^a   Vlotides, George ^a   Spöttl, Gerald ^a   Zhang, Shengwen ^b   Datta, Rakesh ^b   Culler, Michael ^b   Göke, Burkhard ^a   Auernhammer, Christoph J ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b IPSEN   (France)

Author keywords

Gastroenteropancreatic system; Neuroendocrine tumors; Somatostatin receptors

Indexed keywords

BIM 23023; BIM 23A 758; BIM 23A 760; BIM 53097; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SOMATOSTATIN RECEPTOR 2; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CARCINOID; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; HUMAN; HUMAN CELL; MIDGUT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CARCINOID TUMOR; CELL LINE, TUMOR; CELL SURVIVAL; DOPAMINE; HUMANS; INTESTINAL NEOPLASMS; RECEPTORS, DOPAMINE D2; RECEPTORS, SOMATOSTATIN; RECOMBINANT FUSION PROTEINS; SOMATOSTATIN; TRANSCRIPTOME;

EID: 84886415154     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000353784     Document Type: Article

References (36)

1. Brazeau P, et al: Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77-79.
2. Reichlin S: Somatostatin. N Engl J Med 1983; 309: 1495-1501.
3. Moller LN, et al: Somatostatin receptors. Biochim Biophys Acta 2003; 1616: 1-84.
4. Culler MD, et al: Somatostatin analogs for the treatment of neuroendocrine tumors. Cancer Metastasis Rev 2011; 30(suppl 1):9-17.
5. Florio T: Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci 2008; 13: 822-840.
6. Florio T, et al: Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology 2003; 144: 1574-1584.
7. Murray RD, Melmed S: A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 2008; 93: 2957-2968.
8. Modlin IM, et al: Review article: Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010; 31: 169-188.
9. Bruns C, et al: SOM230: A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002; 146: 707-716.
10. Rinke A, et al: Placebo-controlled, doubleblind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-4663.
11. Rocheville M, et al: Subtypes of the somatostatin receptor assemble as functional homo-and heterodimers. J Biol Chem 2000; 275: 7862-7869.
12. Rocheville M, et al, Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000; 288: 154-157.
13. Saveanu A, et al: Bim-23244, a somatostatin receptor subtype 2-and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 2001; 86: 140-145.
14. Ren SG, et al: Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. J Clin Endocrinol Metab 2003; 88: 5414-5421.
15. Jaquet P, et al: Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol 2005; 153: 135-141.
16. Srirajaskanthan R, et al: Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies. Neuroendocrinology 2009; 89: 308-314.
17. Diakatou E, et al: Somatostatin and dopamine receptor profile of gastroenteropancreatic neuroendocrine tumors: An immunohistochemical study. Endocr Pathol 2011; 22: 24-30.
18. Brand S, et al: IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol 2006; 290:G827-G838.
19. Schmittgen TD, Livak KJ: Analyzing realtime PCR data by the comparative C(T) method. Nat Protoc 2008; 3: 1101-1108.
20. Zitzmann K, et al: Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells. Biochem Biophys Res Commun 2006; 344: 1334-1341.
21. Nicoletti I, et al: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139: 271-279.
22. Kidd M, et al: Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines. Cancer 2008; 113: 690-700.
23. Li SC, et al: The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells. PLoS One 2012; 7:e48411.
24. An JJ, et al: Anti-proliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells. Mol Cell Endocrinol 2003; 206: 49-62.
25. Renner U, et al: Heterogeneous dopamine D2 receptor subtype messenger ribonucleic acid expression in clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 1998; 83: 1368-1375.
26. Pivonello R, et al: Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. J Clin Endocrinol Metab 2004; 89: 1674-1683.
27. Sarkar DK, et al: Dopamine, dopamine D2 receptor short isoform, transforming growth factor (TGF)-beta1, and TGF-beta type II receptor interact to inhibit the growth of pituitary lactotropes. Endocrinology 2005; 146: 4179-4188.
28. Takeuchi Y, Fukunaga K: Differential subcellular localization of two dopamine D2 receptor isoforms in transfected NG108-15 cells. J Neurochem 2003; 85: 1064-1074.
29. O'Toole D, et al: The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies. Eur J Endocrinol 2006; 155: 849-857.
30. Saveanu A, et al: Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J Clin Endocrinol Metab 2002; 87: 5545-5552.
31. Nilsson O, et al: GOT1 xenografted to nude mice: A unique model for in vivo studies on SSTR-mediated radiation therapy of carcinoid tumors. Ann NY Acad Sci 2004; 1014: 275-279.
32. Florio T, et al: Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: A multi-center study. Endocr Relat Cancer 2008; 15: 583-596.
33. Junn E, Mouradian MM: Apoptotic signaling in dopamine-induced cell death: The role of oxidative stress, p38 mitogen-activated protein kinase, cytochrome c and caspases. J Neurochem 2001; 78: 374-383.
34. Ferone D, et al: The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology. J Mol Endocrinol 2009; 42: 361-370.
35. Theodoropoulou M, et al: Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res 2006; 66: 1576-1582.
36. Culler MD: Somatostatin-dopamine chimeras: A novel approach to treatment of neuroendocrine tumors. Horm Metab Res 2011; 43: 854-857.